摘要
以５１例晚期肿瘤患者作为研究对象，对其不同来源的肿瘤浸润淋巴细胞（ＴＩＬ）进行治疗研究，发现肿瘤组织来源的ＴＩＬ其有效率及一年生存率明显高于胸腹水及转移淋巴结的ＴＡＬ；其中肿瘤组织的ＴＩＬ，胸腹水、转移淋巴结的ＴＡＬ有效率分别为８０．９％、４０．０％、４６．６％；三者治疗肿瘤患者的一年生存率分别为８１．０％、４６．７％、６０．０％；另外发现胸腹水ＴＡＬ对实质性肿块治疗疗效较低，为４０％，其中静脉滴注更差，为１４．２％，而介入注射与局部治疗较好，为６２．５％；胸腹水ＴＡＬ对癌性胸腹水有一定疗效，以胸腹腔注射为最佳注射途径，消退率为７４％，高于静脉滴注２８．５％；对胸腹水治疗后不消退者进行分析，可能与肿瘤患者的病情有关，影响了ＴＡＬ的吸收。提示治疗实质性肿瘤以ＴＩＬ效果较佳，而ＴＡＬ对胸腹水有一定疗效，且以胸腹腔注射为最佳治疗途径。
We have analysed the anticancer efficacy and one year overal survial rate of 51 patients treated with different source TILs.The efficacy rate(80.9%)and one year overal survial rate(81%)of TIL from solid tumors were higher than that of TAL from ascites and lymph nodes.The efficacy rate of TAL from ascites treated with sold tumor was 40%(vein injection 14.2%,local injection 62.5%).TAL was effective for ascite regression(local injection 74%,vein injection 28.5 %).It showed that TIL killed solid tumor more efficiently than TAL and TAL had effect on ascite regression by local injection.
出处
《免疫学杂志》
CAS
CSCD
北大核心
1996年第4期251-253,共3页
Immunological Journal
